News | April 30, 2026
RPG Life Sciences reports Rs 707.5 crore revenue in FY26, 8% annual growth
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Patalganga plant received zero observation from USFDA earlier
The agreement could rise to $900 million if key commercial milestones are met
The Danish biotech company confirmed the global study will begin in the second half of 2026
CPHI India from 23–25 November 2026 at Yashobhoomi (India International Convention and Expo Centre), while PMEC India from 24–26 November 2026 at India Expo Mart
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
SPARC enters definitive agreement to monetise rare paediatric disease PRV, unlocking capital for R&D and strategic growth
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
Subscribe To Our Newsletter & Stay Updated
